Skip to content

A promising pipeline

Take a closer look at the progress of our first-in-class therapeutics.

Drug Indication* Phase I Phase II Phase III NDA Review Commercialization Rights
(ex-Japan and S. Korea)
Pruritus
Pruritus KORSUVA™ Injection Pruritus CKD-HD§ Commercial Rights: US-Vifor
EU / Other-VFMCRP||
FDA PRIORITY REVIEW
US-Vifor
EU / Other-VFMCRP||
Oral KORSUVA™ Pruritus NDD-CKD Commercial Rights: Cara
Cara
Oral KORSUVA™ Pruritus AD Commercial Rights: Cara
Cara
Oral KORSUVA™ Pruritus PBC Commercial Rights: Cara
Cara
Oral KORSUVA™ Pruritus NP Commercial Rights: Cara
Cara
  1. *Cara Therapeutics has investigated KORSUVA™ for post-operative pain.
  2. Vifor has commercial rights in Non-US Fresenius Medical Care dialysis clinics under a profit-share arrangement.
  3. Commercialization rights to KORSUVA™ in defined indications—Japan: Maruishi Pharma; South Korea: CKD Pharma.
  4. §PDUFA date is August 23, 2021.
  5. ||VFMCRP and Cara have rights to promote in Fresenius clinics in the US under a profit-share agreement.
  6. CKD-HD: Chronic Kidney Disease-Hemodialysis; NDD—CKD: Non-Dialysis Dependent-Chronic Kidney Disease; AD: Atopic Dermatitis; PBC: Primary Biliary Cholangitis; NP: Notalgia Paresthetica.

The United States Food and Drug Administration (FDA) has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. Difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.